On July 28, 2014, Horizon Pharma, Inc. (NASDAQ:HZNP) filed a Form 8-K with the SEC disclosing that two pharmacy benefit managers, CVS Caremark (NYSE:CVS) and Express Scripts, Inc. (NASDAQ:ESRX), expect to announce DUEXIS® and VIMOVO® will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. In the first quarter 2014, DUEXIS® and VIMOVO® accounted for 92% of Horizon's net product sales. Horizon estimates 20-30% of its DUEXIS® and VIMOVO® prescriptions could be at risk by being excluded from the these formularies.
Exclusion from formulary listing means patients will have to cover the full cost of the drug out-of-pocket. One month of DUEXIS®, a combination ibuprofen...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|